Chromosome Aberrations ; Consensus ; Cytogenetics ; Humans ; Multiple Myeloma

Microsatellite instability (MSI) which resulted from the deficiency of DNA mismatch repair (MMR), is an important clinical significance in the related solid tumors, such as colorectal cancer and endometrial cancer. There are several methods to detect MSI status, including immunohistochemistry for MMR protein, multiplex fluorescent polymerase chain reaction (PCR) for microsatellite site and MSI algorithm based on next generation sequencing (NGS). The consensus elaborates the definition and clinical significance of MSI as well as the advantages and disadvantages of the three detection methods. Through this expert consensus, we hope to promote the screening which based on MSI status in malignant tumors and improve the acknowledge of clinicians about various testing methods. Thereby, they could interpret the results more accurately and provide better clinical services to patients.
Antineoplastic Agents ; administration & dosage ; adverse effects ; therapeutic use ; China ; Colorectal Neoplasms ; genetics ; pathology ; Consensus ; DNA Mismatch Repair ; DNA Sequence, Unstable ; Delivery of Health Care ; standards ; Endometrial Neoplasms ; Female ; Humans ; Immunohistochemistry ; Microsatellite Instability ; Microsatellite Repeats ; Microscopy, Fluorescence ; Polymerase Chain Reaction ; Practice Guidelines as Topic

The liver is the most common anatomical site for hematogenous metastases of colorectal cancer, and colorectal liver metastases is one of the most difficult and challenging points in the treatment of colorectal cancer. In order to improve the diagnosis and comprehensive treatment in China, the Guidelines have been edited and revised for several times since 2008, including the overall evaluation, personalized treatment goals and comprehensive treatments, to prevent the occurrence of liver metastases, improve the resection rate of liver metastases and survival. The revised Guideline includes the diagnosis and follow-up, prevention, MDT effect, surgery and local ablative treatment, neoadjuvant and adjuvant therapy, and comprehensive treatment, and with advanced experience, latest results, detailed content, and strong operability.
Chemotherapy, Adjuvant ; China ; Colorectal Neoplasms ; pathology ; Hepatectomy ; Humans ; Liver Neoplasms ; diagnosis ; secondary ; therapy ; Neoadjuvant Therapy ; Practice Guidelines as Topic

Incidence of adenocarcinoma of esophago-gastric junction (AEG) in China presents an obviously increasing trend. Due to the particular anatomic site, its definition, classification, staging, surgical approach, resection pattern, extent of lymphadenectomy, and neoadjuvant therapy, etc. remain controversial. The goal of this expert consensus is to improve the homogeneity in understanding and practice among Chinese thoracic and gastrointestinal surgeons, and to further standardize surgical treatment of AEG. This consensus was generated based on the best available clinical evidence, the latest global guidelines or consensuses, and the agreement from the Chinese expert panel. The panel composed of 19 thoracic surgeons and 20 gastrointestinal surgeons nationwide. Delphi technique was used to generate agreement rates and revision details. In the fields of aforementioned controversies, the present consensus produced 27 statements on surgical treatment-related recommendations for AEG, as well as 9 issues as investigational surgical concerns. The present consensus consists of 7 parts:(1) definition and classification of AEG; (2) surgical approach; (3) minimally invasive surgery; (4) pattern and extent of resection; (5) combined organ resection; (6) lymph node group and lymphadenectomy standard; and(7) neoadjuvant therapy. Pending issues in this consensus need further high-quality clinical research.
Adenocarcinoma ; surgery ; China ; Consensus ; Esophageal Neoplasms ; surgery ; Esophagogastric Junction ; Humans ; Lymph Node Excision ; Neoplasm Staging ; Stomach Neoplasms

OBJECTIVE To provide standardized guidance for the clinical application and management of biosimilars， and promote their widespread and rational use in clinical treatment. METHODS The design， planning， and drafting process as well as the full report of Evidence-based Guideline for the Management of Clinical Application of Biosimilars in China （2024 Edition） followed the WHO Handbook for Guideline Development （2nd edition）， which fully considered the best current evidence from evidence-based medicine， multidisciplinary expert experience， and patient preferences and values. Grading of Recommendations Assessment， Development， and Evaluation （GRADE） approach was adopted to evaluate the quality of evidence and determine the strength of recommendations. RESULTS & CONCLUSIONS Evidence-based Guideline for the Management of Clinical Application of Biosimilars in China （2024 Edition） presented 10 recommendations including 7 strong recommendations and 3 weak recommendations. The recommendations covered the entire process of clinical application and management of biosimilars. Medical institutions and relevant health regulatory departments can refer to this guideline for the scientific management of the extrapolation of unapproved indications of biosimilars. Healthcare providers can refer to this guideline for pre-treatment assessments， patient education， pre-treatment regimen before administration， and dosage regimen adjustments. Multidisciplinary medical teams can refer to this guideline to provide pharmacovigilance and patient management throughout the treatment process.